Mobile website
Clinical Research
Immune function and life quality in patients with advanced non-small cell lung cancer following treatment with autologous cytokine-induced killer cells
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the effectiveness and safety of autologous cytokine-induced killer cells in the treatment of advanced non-small cell lung cancer (NSCLC) after radiotherapy and chemotherapy. Methods: A total of 72 patients with advanced NSCLC who were admitted to our department between June, 2012 and March, 2014 and had undergone radiotherapy and chemotherapy were enrolled. One month after the last radiotherapy and chemotherapy, 38 patients were treated with autologous cytokine-induced killer (CIK) cells for two cycles (5 days each) with an interval of 2 months in addition to the optimal maintenance treatment regimen and the remaining 34 patients were given maintenance treatment only as controls. One week before and one week after treatment with CIK cells, proportions of CD3 +, CD4 +, CD8 +, CD4 +/CD8 +, and CD4 +CD25 + regulatory T (Treg) cells in the peripheral blood were determined by flow cytometry, levels of IL-2, IL-12 and IFN-γ were measured with ELISA, and the Karnofsky performance score (KPS) was calculated. Results: The proportion of CD4 + T cells and the CD4/CD8 + T cell ratio were significantly higher (P<0.05), the proportion of CD4 +CD25 + Treg cells was significantly lower (P<0.05), the levels of IL-12, IFN-γ were significantly increased (P<0.01), and the KPS score was significantly higher (P<0.05) in patients receiving autologous CIKs as compared with control subjects. None of the patients suffered from transient fever or chills in the process of CIK transfusion, and no other side effects were observed. Conclusion: Autologous CIKs may improve the immune function and the quality of life in patients with advanced NSCLC, thus offering an effective and safe treatment option for NSCLC.
Keywords:
Project Supported:
Clc Number:
